OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Soliman on the Rationale for Using Immunotherapy in TNBC

August 4th 2020

Hatem Soliman, MD, discusses the rationale for using immunotherapy in triple-negative breast cancer.

Dr. Agarwal on the Safety Profile of Olaparib in HRR Gene-Mutant mCRPC

August 4th 2020

Neeraj Agarwal, MD, discusses the safety profile of olaparib in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.

Dr. Shaughnessy on Challenges With CAR T-Cell Therapy in Hematologic Malignancies

August 4th 2020

Paul J. Shaughnessy, MD, discusses challenges with CAR T-cell therapy in relapsed/refractory hematologic malignancies.

Dr. Wang on the Safety Profile of Brexucabtagene Autoleucel in Relapsed/Refractory MCL

August 3rd 2020

Michael Wang, MD, discusses the safety profile of the CAR T-cell therapy brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma.

Dr. Mirza on Final Data of the NSGO-AVANOVA2/ENGOT-OV24 Trial in Ovarian Cancer

August 3rd 2020

Mansoor Raza Mirza, MD, discusses the final survival analysis of the phase 3 NSGO-AVANOVA2/ENGOT-OV24 trial in recurrent, platinum-sensitive ovarian cancer.

Dr. Choueiri on Expanding the Therapeutic Armamentarium in mRCC

August 3rd 2020

Toni K. Choueiri, MD, discusses current and emerging treatment options for patients with metastatic renal cell carcinoma.

Dr. Gandara on the Impact of Immunotherapy on the Tumor Microenvironment in Lung Cancer

August 3rd 2020

David R. Gandara, MD, discusses the impact of immunotherapy on the tumor microenvironment in lung cancer.

Dr. Kundranda on the Need for Novel Treatments in Pancreatic Ductal Adenocarcinoma

August 3rd 2020

Madappa Kundranda, MD, PhD, discusses the need to develop novel treatments in pancreatic ductal adenocarcinoma.

Dr. Mesa on the Potential Utility of CAR T-Cell Therapy in MPNs

August 3rd 2020

Ruben A. Mesa, MD, discusses the potential utility of CAR T-cell therapy in myeloproliferative neoplasms.

Dr. Shore on Unique Challenges in Nonmetastatic CRPC

August 3rd 2020

Neal D. Shore, MD, FACS, discusses unique challenges in nonmetastatic castration-resistant prostate cancer.

Dr. Palmer on Complications of Acute Graft-Versus-Host Disease

August 3rd 2020

Jeanne M. Palmer, MD, discusses common complications associated with acute graft-versus-host disease.

Dr. Usmani on Key Findings From the SWOG 1211 Trial in High-Risk Multiple Myeloma

August 3rd 2020

Saad Z. Usmani, MD, FACP, discusses the key takeaways from the randomized phase 2 SWOG 1211 trial in patients with newly diagnosed, high-risk multiple myeloma.

Dr. O’Regan on Biomarkers of Response to CDK4/6 Inhibitors in Breast Cancer

July 31st 2020

Ruth O’Regan, MD, discusses biomarkers of response to CDK4/6 inhibitors in breast cancer.

Dr. Schwartz on the Updated Design of the Alliance A091401 Trial in Metastatic Sarcomas

July 31st 2020

Gary K. Schwartz, MD, discusses the updated design of the phase 2 Alliance A091401 trial for metastatic sarcomas.

Dr. Khong on Endocrine Therapy Combinations in ER+/HER2- Breast Cancer

July 31st 2020

Hung Khong, MD, discusses antiestrogen and immunotherapy combinations in ER-positive, HER2-negative breast cancer.

Dr. Ghosh on the Benefits of Lisocabtagene Maraleucel in Relapsed/Refractory NHL

July 31st 2020

Nilanjan Ghosh, MD, PhD, discusses the utility of lisocabtagene maraleucel in relapsed/refractory non-Hodgkin lymphoma.

Dr. Sabari on Biomarkers of Response to Immunotherapy in Advanced NSCLC

July 31st 2020

Joshua K. Sabari, MD, discusses the need for additional biomarkers of response to immunotherapy in driver-negative advanced non–small cell lung cancer.

Dr. Roland on the Rationale for a Neoadjuvant Checkpoint Blockade in Sarcoma

July 30th 2020

Christina L. Roland, MD, PhD, discusses the rationale for a phase 2 study evaluating neoadjuvant checkpoint blockade study in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Dr. Shaughnessy on the Promise of CAR T-Cell Therapy in Hematologic Malignancies

July 30th 2020

Paul J. Shaughnessy, MD, discusses the promising future of CAR T-cell therapy in relapsed/refractory hematologic malignancies.

Dr. Morris on Next Steps for PSMA–Targeted PET Imaging in Prostate Cancer

July 30th 2020

Michael J. Morris, MD, discusses next steps for prostate-specific membrane antigen–targeted PET imaging in prostate cancer.